Skip to main content

Table 2 Baseline biomarker and patient characteristics by treatment assignment

From: Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study

  PCI (N = 37) MED (N = 33)  
  n % (mean ± sd) median{interquartile range}* n % (mean ± sd) median{interquartile range}* p-value
Biomarkers      
  Baseline NT-proBNP(ng/L){IQR} 37 846.1{402.4,1488} 33 1100{474.6,1726} 0.306
  Baseline VEGF(pg/mL){IQR} 31 42.5{23.6,207.2} 27 37.5{17.4,70.2} 0.293
  Baseline MMP-2(ng/mL){IQR} 33 185.7{172.3,216.9} 28 185.3{172.1,239.7} 0.879
  Baseline MMP-9(ng/mL){IQR} 33 90{56,185} 28 102.3{44.2,163.2} 0.506
  Baseline TIMP-2(ng/mL){IQR} 33 64.5{57.6,74.1} 28 64.3{59.2,70} 0.789
  Baseline GALECTIN(ng/L){IQR} 33 12.8{9.8,15.5} 28 13{9.2,14.9} 0.806
Age (years) 37 (62.5 ± 9.1) 33 (58.8 ± 8.1) 0.086
Female 11 29.7 6 18.2 0.261
Race White 37 100 33 100 .
Clinical History      
  Angina 8 21.6 7 21.2 0.967
  Myocardial infarction 1 2.7 2 6.1 0.599
  Percutaneous coronary intervention 3 8.1 1 3 0.616
  Congestive heart failure 0 0 1 3 0.471
  Hypertension 21 56.8 15 45.5 0.345
  Diabetes 2 5.4 8 24.2 0.038
  Insulin use 1 2.7 5 15.2 0.093
  Hypercholesterolemia 15 40.5 16 48.5 0.504
  Stroke 2 5.4 2 6.1 1.000
  Cerebrovascular disease 2 5.4 3 9.1 0.661
  Peripheral vascular disease 1 2.7 0 0 1.000
  Current Smoker 13 35.1 12 36.4 0.915
  Family history CAD 12 32.4 17 51.5 0.106
Days from MI to randomization - median {IQR} 37 22{17–26} 33 20{14–25} 0.135
Index myocardial infarction      
  Received thrombolytics 1 2.7 0 0 1.000
  STE / Q wave / R loss 30 81.1 28 84.8 0.676
  Killip Class II-IV 7 18.9 4 12.1 0.522
  Ejection fraction 37 (46.8 ± 9) 33 (45.7 ± 10.5) 0.652
  Rales 0 0 1 3.1 0.464
Clinical measures      
  Estimated GFR <60 ml/min/1.73 m2 5 13.5 3 9.1 0.714
  Glucose > =126 mg/dl 2 5.6 6 18.2 0.140
  BMI (kg/m2) 37 (26.4 ± 2.8) 32 (27.2 ± 4.3) 0.365
  Heart rate (bpm) 37 (68.9 ± 9.4) 33 (69.7 ± 10.3) 0.733
  Systolic blood pressure (mmHg) 37 (119.5 ± 11.4) 33 (121.4 ± 12.5) 0.507
Angiography      
  Infarct-related artery (IRA) LAD 13 35.1 6 18.2 0.240
  Infarct-related artery (IRA) Lcx 6 16.2 5 15.2
  Infarct-related artery (IRA) RCA 18 48.6 22 66.7
  Angiography - multivessel disease 9 24.3 12 37.5 0.236
  Collaterals 36 97.3 28 87.5 0.175
Medications      
  Aspirin 36 97.3 32 97 1.000
  Thienopyridine 34 91.9 8 24.2 <.001
  Warfarin 0 0 3 9.1 0.100
  Beta blocker 32 86.5 33 100 0.056
  Ca blocker 1 2.7 1 3 1.000
  Lipid lowering agent 35 94.6 33 100 0.494
  Spironolactone 6 16.2 3 9.1 0.485
  ACE-Inhibitor or ARB 32 86.5 30 90.9 0.714
  1. *median(interquartile range) for biomarkers, ACE-angiotensin converting enzyme, ARB-angiotensin receptor blocker, BMI-body mass index, BP = blood pressure, CAD-coronary artery disease, GFR-glomerular filtration rate, IQR-interquartile ranges, IRA-infarct related artery, LAD-left anterior descending artery, LCX-left circumflex coronary artery, MED – medical therapy alone, PCI- percutaneous coronary intervention, RCA-right coronary artery, STE-ST elevation.